Methanimine derivative (BN3) alleviates obesity-associated neurobehavior alteration by influencing metabolic and neuroinflammatory gene pathways in in-vivo zebrafish model | Synapse
March 3, 2026
Methanimine derivative (BN3) alleviates obesity-associated neurobehavior alteration by influencing metabolic and neuroinflammatory gene pathways in in-vivo zebrafish model
Key Points
BN3 treatment significantly improves neurobehavioral outcomes in zebrafish models of obesity.
The intervention effectively influences both metabolic pathways and neuroinflammatory gene pathways.
Assessment using in-vivo zebrafish model explores the effects of BN3 on obesity-related changes.
Further research may clarify the potential therapeutic roles of BN3 in treating obesity-related neurobehavioral issues.